CORRECTION OF LIPID DISTURBANCES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ACCORDANCE WITH CURRENT INTERNATIONAL STANDARDS AND GUIDELINES
- Authors: Susekov A.1
-
Affiliations:
- Russian Cardiology Research and Production Complex, Ministry of Health and Social Development
- Issue: Vol 23, No 4 (2012)
- Pages: 19-22
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115418
- ID: 115418
Cite item
Open Access
Access granted
Abstract
The paper discusses the general principles of drug correction for lipid disturbances in patients with type 2 diabetes mellitus in accordance with current American and European Scientific Guidelines.
Full Text
About the authors
A. Susekov
Russian Cardiology Research and Production Complex, Ministry of Health and Social Development
Email: asus99@mail.ru
MD Moscow
References
- Catapano A., Backer G., Graham I. et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)//Atherosclerosis. - 2011; 217: 3-46.
- Executive Summary: Standards of Medical Care in Diabetes//Diabetes Care 35. -2012; 1: 4-10.
- The ACCORD Study Group. Effects of combination lipid-lowering therapy in type Diabetes Mellitus. New Engl. J. Med. 2010. Epub ahead a print. NEJM//Org. N. Engl. J. Med. - 2010; 362 (17): 1563-1574.
- Robinson J., Stone N. et al. Identifying patients for aggressive cholesterol lowering: the risk curve concept//Am. J. Cardiology. - 2006; 98: 1405-1408.
- Haffer S., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without myocardial inf arction//N. Engl. J. Med. - 1998; 339: 229-234.
- Stamler J., Vaccano O., Neaton J. et al. Diabetes, other risk-factors, and 12-year mortality for men, screened in the Multiply Risk Factor Intervention//Trial. Diabetes. Care. - 1993; 16: 434-444.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)//Lancet. - 1994; 344: 1383-1389.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial//Lancet. - 2002; 360: 7-22.
- Colhoun H., Betteridge D., Durrington P. et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS)//Diabetologia. - 2005; 48 (12): 2482-2485.
- Shepherd J., Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to New Targets (TNT) Study//Diabetes. Care.- 2006; 29: 1220-1226.
- Steiner G., Stewart D., Hosking J. Baselinecharacteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes//Am. J. Cardiol. - 1999; 84 (9): 1004-1010.
- Rubins H., Robins S., Collins D. et al. Diabets, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veteran Affaires high-density lipoprotein intervention trial (VA-HIT)//Arch. Intern. Med. - 2002; 162 (22): 2597-2604.
- Frick M., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment; changes in risk factors, and incidence of coronary heart disease//N. Engl.J. Med. - 1987; 317: 1237-1245.
- Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study//Circulation. - 2000; 102: 21-27.
- Keech A., Simes R., Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial//Lancet. - 2005; 366 (9500): 1849-1861.
- Grundy S., Vega G., Tomassini J. et al. Correlation of non-high density lipoprotein cholesterol and low-density lipoprotein cholesterol with apoplipoprotein B during simvsatatin+fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)//Am. J. Cardiol. - 2009; 104 (4): 548-553.
- Jun M., Foote C., Lv J. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis//Lancet. - 2010; 375: 1875-1884.
Supplementary files
